HTL0039732 in Participants With Advanced Solid Tumours
Status:
Recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on
its own (as a monotherapy) and in combination with atezolizumab or with other approved
anti-cancer therapies, in participants with advanced solid tumours.